A study of safety and efficacy of novel targeted therapy combinations in adult patients with advanced or metastatic colorectal cancer.

2023-510379-77-00 Protocol CADPT01C12101 Human pharmacology (Phase I) - Other Ended

Start 5 Aug 2020 · End 26 Sep 2024 · Status Ended · 1 EU/EEA countries · 3 sites · Protocol CADPT01C12101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 74
Countries 1
Sites 3

Advanced or metastatic BRAF V600 colorectal cancer.

Key facts

Sponsor
Novartis Pharma AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
5 Aug 2020 → 26 Sep 2024
Decision date (initial)
2024-06-10
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-510379-77-00
EudraCT number
2019-004688-27
ClinicalTrials.gov
NCT04294160

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced or metastatic BRAF V600 colorectal cancer.

VersionLevelCodeTermSystem organ class
21.0 PT 10061451 Colorectal cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Novartis Pharma AG

Sponsor organisation
Novartis Pharma AG
Address
Lichtstrasse 35
City
Basel
Postcode
4056
Country
Switzerland

Scientific contact point

Organisation
Novartis Pharma AG
Contact name
Novartis Pharma Arzneimittel GmbH

Public contact point

Organisation
Novartis Pharma AG
Contact name
Novartis Pharma Arzneimittel GmbH

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 35 3
Rest of world
Israel, United Kingdom, Australia, Singapore, United States, Canada
39

Investigational sites

Spain

3 sites · Ended
Hospital Universitari Vall D Hebron
#2501: Oncología Médica, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital General Universitario Gregorio Maranon
#2502: Oncología Médica, Calle Del Doctor Esquerdo 46, 28009, Madrid
Hospital Clinico Universitario De Valencia
#2503: Oncología Médica, Avenida Blasco Ibanez 17, 46010, Valencia

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2020-08-05 2020-08-10

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-05 Spain Acceptable
2024-06-10
2024-06-10